Theralase Technologies (CVE:TLT) Trading Up 2.4% - Here's What Happened

Key Points

• Theralase Technologies Inc. shares rose by 2.4% to C$0.22, despite a significant drop in trading volume to 11,505 shares, down 88% from the average.
• The company has a market capitalization of C$52.35 million, a quick ratio of 3.40, and a notable debt-to-equity ratio of 14.85.
• Theralase focuses on the research and development of light activated photo dynamic compounds for treating cancers, bacteria, and viruses, as well as patented laser technology for pain relief.

Theralase Technologies Inc. (CVE:TLT - Get Free Report) shares rose 2.4% during trading on Tuesday . The company traded as high as C$0.23 and last traded at C$0.22. Approximately 11,505 shares changed hands during trading, a decline of 88% from the average daily volume of 94,024 shares. The stock had previously closed at C$0.21.

Theralase Technologies Stock Performance

The stock has a market cap of C$53.57 million, a P/E ratio of -11.72 and a beta of 1.36. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40. The business's 50 day simple moving average is C$0.21 and its 200 day simple moving average is C$0.21.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.